why didn’t AGIX position this as primarily a diabetes drug?
They kinda did - the primary enrollment criteria for ARISE was diabetes. Other possible criteria were fallbacks.
But my guess is that, like a lot of biotechs, they jumped too quickly to ph iii. This, in combo with the fact that the parent drug is primarily a heart drug, resulted in a cardio trial.
Market Data 
Markets 
AI
